Carbon-11 Acetate PET/CT in Diagnosing Participants with Glioma

PRIMARY OBJECTIVES:

I. To determine whether carbon-11 acetate ([11C]acetate) PET imaging can differentiate glioma from normal brain in patients with grades 2, 3 or 4 gliomas by comparison of visual assessment and standardized uptake value (SUV) with standard clinical magnetic resonance (MR) imaging assessment using T2/fluid-attenuated inversion recovery (FLAIR) and gadolinium enhancement.

SECONDARY OBJECTIVES:

I. To compare uptake of [11C]acetate at baseline among untreated grade 2, grade 3, and grade 4 gliomas.

II. To compare uptake of [11C]acetate at baseline among key molecular glioma subgroups (IDH mutant versus [vs.] wildtype [WT]; 1p/19q co-deleted vs intact; and EGFR amplified vs non-amplified).

III. To determine whether uptake of [11C]acetate is decreased in grade 2 glioma patients following treatment with either an IDH inhibitor or with radiation followed by chemotherapy, compared to the same patient’s pre-treatment [11C]acetate uptake.

IV. To determine whether uptake of [11C]acetate is decreased in grade 3 and 4 glioma patients following treatment with concurrent radiation and temozolomide, compared to their pre-treatment uptake.

V. To determine whether uptake of [11C]acetate is changed from uptake after radiation/temozolomide at the time of tumor progression in treated grade 3 and 4 gliomas.

VI. Percentage of patients that experience adverse events by Common Terminology Criteria for Adverse Events, version 3.0.

OUTLINE:

Participants receive carbon-11 acetate intravenously (IV) then undergo PET/CT scan over 30 minutes at baseline and 2-3 months after treatment.

After completion of study treatment, participants are followed up every 6 months.